Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Acting on Cancer Testing-Together Intervention for Improving Adherence in Patients with BRCA Mutations, ACT-Together Trial

Trial Status: closed to accrual

This clinical trial assesses a group-education based intervention called Acting on Cancer Testing-Together (ACT-Together) for improving adherence to recommend surveillance and risk-reducing procedures in patients with BRCA 1 and 2 mutations (changes). BRCA 1 and 2 are hereditary cancer predisposition syndromes and account for up to 3-10% of breast and ovarian cancers. For women with breast cancer genes (BRCA) 1 and 2, adherence to recommended surveillance and use of risk reducing surgery can decrease the risk of cancer-related death, yet use of these strategies remains low. Group-based interventions have been successfully used to improve compliance with breast cancer and cervical cancer screening in diverse populations. This study may help researchers learn whether the ACT-Together intervention may improve adherence to recommended surveillance and risk-reducing procedures in patients with BRCA 1 and 2 mutations.